%D8%B1%D9%8A%D9%81%D8%A7%D8%B3%D8%AA%D9%8A%D8%AC%D9%85%D9%8A%D9%86%D8%B1%DB%8C%D9%88%D8%A7%D8%B3%D8%AA%DB%8C%D9%82%D9%85%DB%8C%D9%86RifastigminRivastigminRivastigmineRivastigmina%D8%B1%DB%8C%D9%88%D8%A7%D8%B3%D8%AA%DB%8C%DA%AF%D9%85%DB%8C%D9%86RivastigmiiniRivastigmine%D7%A8%D7%99%D7%91%D7%A1%D7%98%D7%99%D7%92%D7%9E%D7%99%D7%9FRivasztigmin%D5%8C%D5%AB%D5%BE%D5%A1%D5%BD%D5%BF%D5%AB%D5%A3%D5%B4%D5%AB%D5%B6Rivastigmina%E3%83%AA%E3%83%90%E3%82%B9%E3%83%81%E3%82%B0%E3%83%9F%E3%83%B3RivastigmineRywastygminaRivastigmina%D0%A0%D0%B8%D0%B2%D0%B0%D1%81%D1%82%D0%B8%D0%B3%D0%BC%D0%B8%D0%BDRivastigminRivastigminRivastigmin%D0%A0%D0%B8%D0%B2%D0%B0%D1%81%D1%82%D0%B8%D0%B3%D0%BC%D1%96%D0%BDRivastigmineQ411887
about
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's DiseaseEfficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseRivastigmine as a Treatment for Methamphetamine DependenceComparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive DeclineRivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseNeuromodulation and Language Acquisition (Stage Ib)Neuromodulation and Language Acquisition (Project Stage Ia)Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase InhibitorsMild Cognitive Impairment in Parkinson's DiseaseComparative Research of Alzheimer's Disease DrugsEfficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE StudyCognitive Decline in Non-demented PDStudy for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) PatientsRivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering PhaseComparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's DiseaseCognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After RivastigmineBioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting ConditionsBioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed ConditionsRivastigmine and Huperzine A as Treatments for Cocaine DependenceExelon Patch and Combination With Memantine Comparative TrialRandomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment PatientsRivastigmine for Intensive Care Unit (ICU) DeliriumRIVastigmine In Vascular cognitivE ImpairmentEffect of Heat on Rivastigmine Release and Absorption From Rivastigmine Patch ProductsDeep Brain Stimulation for Alzheimer's DiseaseNoradrenaline, Acetylcholine and Dynamic Learning in Healthy HumansCholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseBrain Changes by Rivastigmine According to Butyrylcholinesterase Alleles16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease PatientsA Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body DiseaseOpen Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVDRivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's DiseaseRivastigmine Patch in Veterans With Cognitive Impairment Following TBITolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's DementiaEffects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease PatientsRivastigmine Study in Adolescents With Down Syndrome
P4844
P769
Rivastigmine for Alzheimer's diseaseEfficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialPotential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature.Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients.A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.High performance liquid chromatographic fluorescence detection method for the quantification of rivastigmine in rat plasma and brain: application to preclinical pharmacokinetic studies in rats.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Rivastigmine transdermal patch: role in the management of Alzheimer's disease.Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Rivastigmine in Parkinson's disease dementia.Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.[Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection].Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition: different effects of donepezil and rivastigmine.Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease.Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation.Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].Tissue distribution and pharmacodynamics of rivastigmine after intranasal and intravenous administration in rats.[Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease].Evaluation of Acute and Chronic Effects of D-Galactose on Memory and Learning in Wistar Rats.Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysisPreparation and evaluation of injectable sustained-release microspheres of rivastigminePisa syndrome secondary to rivastigmine: a case reportDevelopment of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma--optimization of the limits of detection and quantitation
P921
Q11081-3E04282B-76E5-42D7-95FA-85F51142E342Q11081-BB6C2398-8F6A-4A8E-B683-AA3B9222AFC2Q11085-E1252E03-3EC1-4CD2-8F83-1E66AA5A393EQ11085-E7231A70-5ACF-48E7-B28B-8A2DA46A5AC0Q1331905-1B705A35-74A3-43BC-9B6B-57BAB9EEF8F2Q5326566-FF0EF1D0-57B4-4AD8-A463-8A32504127A9Q83030-01CC13E5-8D65-40E2-A9C8-35395356886F
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Rivastigmiini
@fi
Rivastigmin
@de
Rivastigmin
@sh
Rivastigmin
@sr
Rivastigmin
@sv
Rivastigmina
@es
Rivastigmina
@it
Rivastigmine
@nl
Rivastigmine
@vi
Rivasztigmin
@hu
type
label
Rivastigmiini
@fi
Rivastigmin
@de
Rivastigmin
@sh
Rivastigmin
@sr
Rivastigmin
@sv
Rivastigmina
@es
Rivastigmina
@it
Rivastigmine
@nl
Rivastigmine
@vi
Rivasztigmin
@hu
altLabel
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
@cy
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
@en
123441-03-2
@fr
C14H22N2O2
@fr
ENA713
@en
Ena 713 free base
@cy
Ena 713 free base
@en
Exelon
@de
Exelon
@es
Exelon
@fi
prefLabel
Rivastigmiini
@fi
Rivastigmin
@de
Rivastigmin
@sh
Rivastigmin
@sr
Rivastigmin
@sv
Rivastigmina
@es
Rivastigmina
@it
Rivastigmine
@nl
Rivastigmine
@vi
Rivasztigmin
@hu